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Summary Inherited susceptibility to ovarian cancer has been associated with germline defects at several loci. The major known ovarian
cancer susceptibility gene is BRCA1 on chromosome 17q, which confers a risk of approximately 60% by the age of 70 years. Truncating
mutations in BRCA2on chromosome 13q also predispose to ovarian cancer, although they confer a lower risk than mutations in BRCA1. We
have studied the molecular basis of ovarian cancer predisposition in a Finnish family with three affected sisters. Analysis of polymorphic
markers provided evidence against linkage to BRCA1, but the sibship was consistent with linkage to BRCA2. Conformation-sensitive gel
electrophoresis was used to screen the entire coding sequence of BRCA2. A G to A transition at nucleotide 8702 was observed, which is
predicted to convert glycine 2901 to aspartate in the encoded protein. This sequence variant was not detected in 220 cancer-free Finnish
control individuals, or in several hundred cancerfamilies of many nationalities previously screened for BRCA2mutations. Taken togetherwith
the fact that this amino acid residue and the surrounding region of BRCA2 is identical in mouse and chicken, the data suggest that this
alteration is a disease-causing BRCA2 missense mutation. Previously published data indicate that the risks of breast and ovarian cancer
conferred by BRCA2-truncating mutations varies with the position ofthe mutation in the gene. The missense mutation reported here suggests
that the BRCA2 domain including and surrounding glycine 2901 may be more important in preventing neoplastic transformation in ovarian
epithelium than in breast epithelium.
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Ovarian cancer is the sixth most common cancer in women world-
wide (Parkin et al, 1993). It is estimated that 5-10% of ovarian
cancers are associated with the inheritance of a mutant allele
conferring autosomal dominant predisposition with high pene-
trance (Lynch et al, 1987). Genetic linkage studies have indicated
that the majority of hereditary breast-ovarian and site-specific
ovarian cancer families appear to be linked to the BRCAJ gene on
chromosome 17q (Hall et al, 1990; Miki et al, 1994). Mutations in
BRCAJ confer an overall risk of ovarian cancer of approximately
60% by the age of 70 years in high-risk families (Easton et al,
1995), although some other studies have suggested a lower risk
(Struewing et al, 1997; Whittemore et al, 1997).
Mutations in the BRCA2 gene on chromosome 13q (Wooster et
al, 1994; 1995) also confer susceptibility to ovarian cancer. The
risk is lower than that conferred by BRCAJ and has recently been
estimated at 27% (D Ford, DF Easton and the Breast Cancer
Linkage Consortium, submitted for publication). The risks of
breast and ovarian cancer conferred by BRCA2 mutations also
vary according to the position ofthe mutation within the gene. In
particular, the ratio of ovarian cancer to breast cancer cases
observed in each familial cluster appears to be higher in aregion of
approximately 3000 bp within exon 11, which has been termed the
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ovarian cancer cluster region (OCCR) (Gayther et al, 1997). In
principle, this pattern could be due to a lower breast cancer risk
conferred by mutations in the OCCR compared with the rest ofthe
gene; a higher ovarian cancer risk conferred by mutations in the
OCCR compared with the rest of the gene; or both. Whichever
option is correct, however, it appears likely that mutational inacti-
vation ofcertain domains within BRCA2 differentially alters risks
ofbreast and ovarian cancer. Tocharacterize further such domains,
we have analysed a Finnish family in which three sisters devel-
oped ovarian cancer.
MATERIAL AND METHODS
Patients
The method used for identifying a series of Finnish ovarian cancer
families hasbeendescribedinaprevious study (Auranenetal, 1996).
Briefly, patients diagnosed with epithelial ovarian cancer in Finland
between 1980 and 1982 and their first-degree relatives were studied.
Ofthe 559 ovarian cancerprobands, 27 had one ormore first-degree
relatives affected with ovarian cancer. Paraffin-embedded tumour
samples were obtainedfor47 patients belonging to these 27 different
families. Blood samples were obtained from members of a single
family (family 19). This family includes three sisters with epithelial
ovarian cancer. The mother ofthe sisters had died oftuberculosis at
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Figure 1 Pedigree of family 19. Patient 19-1 was diagnosed at the age of 59 years with ovarian cancer, patient 19-2 at the age of 58 years and patient 19-3 at
the age of 55 years. All these three sibs are at present clinically cancer free and alive at the ages of 71, 68 and 63 years respectively. One sister and one
brother have died without evidence of cancer and one brother is alive and cancer free. The germline allele data at the marker loci used are shown beneath each
analysed subject. Below the allele data, electrophoresis analysis of Sfanl digests from patients and one healthy brother are presented. The normal sample
(blood) is indicated with N and tumour samples with T. The upper fragment in the gel is PCR product without sequence variant, digestion of this 194-bp fragment
resulted in 127-bp and 67-bp (not shown) fragments in patients. In patient 19-1 tumour sample showed loss of the wild-type allele
age 41 years and the father died free of cancer at age 71 years. One
sister and one brother have died without evidence of cancer and one
brother is alive and cancer free (Figure 1).
Patient 19-1 has had eight pregnancies and was 55 years of age
at menopause. In 1981, at the age of 59 years, she presented with
post-menopausal bleeding and was diagnosed with a grade III
transitional cell stage Ib ovarian cancer. Patient 19-2 has had one
pregnancy and one miscarriage, and was 52 years at menopause.
In 1983, at the age of 58 years, she presented with loss of weight
and ascites, and was diagnosed with serous papillary grade I stage
HIlc ovarian cancer and in September 1996 she was operated for an
ovarian cancer metastasis in the colon. She received six courses of
cytostatic treatment and is currently in follow-up without clinical
evidence ofdisease. Patient 19-3 has had no pregnancies and was
51 years of age at menopause. In 1986, at the age of55 years, she
was hospitalized because ofacute severe abdominal pains and was
diagnosed with an endometrioid grade II stage Ia ovarian cancer.
All three patients underwent hysterectomy, bilateral salpingo-
oophorectomy and cytostatic treatments. They are currently clini-
cally disease free.
Mutational screen of BRCA2
The entire coding sequence and intron/exon junctions of the
BRCA2 gene were amplified by polymerase chain reaction (PCR)
using previously published primer sequences (Gayther et al,
1997). Both primers were end-labelled with gamma-32P, and
heteroduplexes were formed by heating the PCR products to 98°C
for 10 min, holding at60°C for 15 min and allowing them to return
to room temperature. Samples were then analysed by conforma-
tion-sensitive gel electrophoresis (CSGE) (Ganguly et al, 1993).
Samples showing variant migration patterns were reamplified and
directly sequenced using fluorescent dye terminators and analysed
on an ABI 377 DNA sequencer.
Analysis of G8702A using a PCR restriction enzyme
assay
Screening ofthe G to A change at nucleotide 8702 was performed
by restriction enzyme digestion. The PCR amplification was
performed in a total volume of 50 gl, including 150 ng genomic
DNA, 25 gM of dNTP (Pharmacia Biotech), 0.8 gM of each
primer, 1.5 mM magnesium chloride and 10 x reaction buffer
(Perkin Elmer). The denaturation and synthesis steps were: 1 min
at 95°C for denaturation, 45 s at 56°C for annealing and 1 min at
72°C for synthesis. The three-step amplification cycle was
repeated 40 times. The following primers were used for amplifica-
tion: forward primer5'-TGGTTCTTTAGTTTTlAGTTGCTlTTG;
reverse primer 5'-TCACCTCAAGGTAAGCTGGG.
The digestion was performed with SfaNI restriction enzyme in
1 x NEBuffer 3 (New England BioLabs) at 37°C overnight. SfaNI
enzyme cuts the PCR fragment (194 bp), which contains
mutations in two fragments (127 bp and 67 bp by size), whereas
the wild-type fragment lacks the restriction site and is notdigested.
After digestion, PCR products were electrophoresed through 3%
agarose gels.
RESULTS
Linkage analysis using markers D17S250, DJ7S579, D17S588 and
D17S855 for the BRCAJ locus provided evidence against linkage
to BRCAI, whereas marker D13S310 at the BRCA2 locus was
British Joumal of Cancer (1998) 77(8), 1199-1202
1200 S Roth etal
W1I
0CancerResearch Campaign 1998BRCA2 mutation in three siblings with ovarian cancer 1201
compatible with linkage (Figure 1). CSGE was used to screen the
entire coding sequence of the BRCA2 gene. The only variant
detected was a G to A transition at nucleotide 8702, which is
predicted to convert glycine to aspartate at amino acid 2901. This
variant was present in all three sisters with ovarian cancer.
Analysis of tumour material from one case showed loss of
heterozygosity of the allele not carrying the sequence variant
(Figure 1). To evaluate further the significance ofthis finding, we
analysed 220 Finnish cancer-free controls and detected it in none.
We also analysed 190 Finnish patients with primary ovarian
cancer. A total of 44 of these ovarian cancer cases were familial
and derived from 26 different families (Auranen et al, 1996).
Among the other 146 cases there was a series of 15 patients who
were selected by age (younger than 40 years at the time of diag-
nosis). The remaining 131 cases were unselected. The G8702A
change was also searched for in index patient DNA samples for
100 Finnish breast cancer families (with three or more cases of
breast or ovarian cancer in first- or second-degree relatives, all
probands affected with breast cancer) previously analysed for
BRCA1 and BRCA2 mutations. Ten of these patients were
BRCA1 mutation carriers and 11 carried BRCA2 mutations,
whereas 65 breast cancer only families and 15 breast-ovarian
families were negative for both (Vehmanen et al, 1997). In addi-
tion, 21 breast cancerfamilies not scrutinized forthe above criteria
(not previously analysed for BRCA1 or BRCA2) were studied for
G8702A variant. None of these 311 patients or 220 cancer-free
controls showed the change.
DISCUSSION
We have detected a BRCA2 sequence variant that is predicted to
generate a missense amino acid change in a family with three
sisters affected by ovarian cancer. Until this variant is evaluated in
a functional assay for BRCA2, it will not be possible to determine
unambiguously ifit is adisease associated mutation or a rare poly-
morphism. However, the variant has not been detected in a large
series of Finnish controls and has not been reported previously in
several hundred individuals screened. It is present in all three
sisters with ovarian cancer, and the one tumour sample examined
showed loss of the other allele (as predicted for a tumour-
suppressor gene and previously demonstrated for cancers in
BRCA2 mutation carriers). Moreover, in a protein that shows only
59% sequence identity between human and mouse, Gly-2901 is
conserved in human, mouse and chicken, and is situated within a
domain ofthe protein that shows strong sequence conservation in
these three species (Table 1). Taken together, the evidence indi-
cates that this is likely to be a disease-associated BRCA2 mutation.
Truncating BRCA2 mutations associated with a high ratio of
ovarian to breast cancer have previously been mapped to the
OCCR within exon 11. This is the first BRCA2 family reported
with more than two cases ofovarian cancer and a mutation outside
this region. Unfortunately, it has not been possible to evaluate
further the cancer risks associated with this mutation because we
have failed to detect additional examples of the variant in other
Finnish ovarian orbreast cancer families, orin aconsecutive series
of ovarian cancer cases. Nevertheless, given the rarity of such
ovarian cancer clusters associated with BRCA2 mutations, we
propose that this variant is associated with different breast/ovarian
risks compared with mutations elsewhere in the gene. Whetherthis
is a result of an increased ovarian cancer risk, decreased breast
cancer risk or both is impoEFible to evaluate at present. However,
Table 1 A stretch of amino acid sequence of human, mouse and chicken
BRCA2
Human SRALTRQQVRALQDG*AELYEAVKNAADPAYL E
Mouse SRTLTRQQVHALQDGAELYAAVQYASDPDHLE
Chick SR IVTRQQ I HNLQDGAELYEAIQNAADPSYME
The target of the mutation, amino acid Gly-2901 (*), is conserved in human,
mouse and chicken, and is located within a domain of the protein that shows
strong sequence conservation in these three species (amino acid residues
that are identical in all three species are shown in bold).
the results suggest that inactivation of the BRCA2 domain that
includes glycine 2901 may have different effects on breast and
ovarian epithelium from inactivation of other domains of the
protein.
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